Sandbox: maria6

Jump to navigation Jump to search

WikiDoc Resources for Sandbox: maria6

Articles

Most recent articles on Sandbox: maria6

Most cited articles on Sandbox: maria6

Review articles on Sandbox: maria6

Articles on Sandbox: maria6 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Sandbox: maria6

Images of Sandbox: maria6

Photos of Sandbox: maria6

Podcasts & MP3s on Sandbox: maria6

Videos on Sandbox: maria6

Evidence Based Medicine

Cochrane Collaboration on Sandbox: maria6

Bandolier on Sandbox: maria6

TRIP on Sandbox: maria6

Clinical Trials

Ongoing Trials on Sandbox: maria6 at Clinical Trials.gov

Trial results on Sandbox: maria6

Clinical Trials on Sandbox: maria6 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sandbox: maria6

NICE Guidance on Sandbox: maria6

NHS PRODIGY Guidance

FDA on Sandbox: maria6

CDC on Sandbox: maria6

Books

Books on Sandbox: maria6

News

Sandbox: maria6 in the news

Be alerted to news on Sandbox: maria6

News trends on Sandbox: maria6

Commentary

Blogs on Sandbox: maria6

Definitions

Definitions of Sandbox: maria6

Patient Resources / Community

Patient resources on Sandbox: maria6

Discussion groups on Sandbox: maria6

Patient Handouts on Sandbox: maria6

Directions to Hospitals Treating Sandbox: maria6

Risk calculators and risk factors for Sandbox: maria6

Healthcare Provider Resources

Symptoms of Sandbox: maria6

Causes & Risk Factors for Sandbox: maria6

Diagnostic studies for Sandbox: maria6

Treatment of Sandbox: maria6

Continuing Medical Education (CME)

CME Programs on Sandbox: maria6

International

Sandbox: maria6 en Espanol

Sandbox: maria6 en Francais

Business

Sandbox: maria6 in the Marketplace

Patents on Sandbox: maria6

Experimental / Informatics

List of terms related to Sandbox: maria6

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: Occult cancer; CUP; Metastases of unknown primary origin; Unknown primary origin neoplasm; cancers of unknown primary site; neoplasms of unknown primary site

Overview

Historical Perspective

  • Cancer of unknown primary origin was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of cancer of unknown primary origin.
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose cancer of unknown primary origin.

Classification

  • Cancer of unknown primary origin may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of cancer of unknown primary origin include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of Cancer of unknown primary origin is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of cancer of unknown primary origin, involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of Cancer of unknown primary origin.
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of Cancer of unknown primary origin.

Causes

  • Cancer of unknown primary origin may be caused by either [cause1], [cause2], or [cause3].
  • Cancer of unknown primary origin is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
  • There are no established causes for cancer of unknown primary origin.

Differentiating Cancer of Unknown Primary Origin from Other Diseases

  • Cancer of unknown primary origin must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of cancer of unknown primary origin is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of Cancer of unknown primary origin was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop cancer of unknown primary origin.
  • Cancer of unknown primary origin is more commonly observed among patients aged [age range] years old.
  • Cancer of unknown primary origin is more commonly observed among [elderly patients/young patients/children].

Gender

  • Cancer of unknown primary origin affects men and women equally.
  • [Gender 1] are more commonly affected with cancer of unknown primary origin than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for cancer of unknown primary origin.
  • Cancer of unknown primary origin usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop Cancer of unknown primary origin.

Risk Factors

  • Common risk factors in the development of cancer of unknown primary origin are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with cancer of unknown primary origin remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with Cancer of unknown primary origin may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of Cancer of unknown primary origin include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with Cancer of unknown primary origin is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of cancer of unknown primary origin is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • Cancer of unknown primary origin is usually asymptomatic.
  • Symptoms of cancer of unknown primary origin may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with cancer of unknown primary origin usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with cancer of unknown primary origin.
  • A [positive/negative] [test name] is diagnostic of cancer of unknown primary origin.
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of Cancer of unknown primary origin.
  • Other laboratory findings consistent with the diagnosis of Cancer of unknown primary origin include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with cancer of unknown primary origin.
  • [Imaging study 1] is the imaging modality of choice for cancer of unknown primary origin.
  • On [imaging study 1], Cancer of unknown primary origin is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • Cancer of unknown primary origin may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for cancer of unknown primary origin; the mainstay of therapy is supportive care.
  • The mainstay of therapy for cancer of unknown primary origin is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for cancer of unknown primary origin.
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of Cancer of unknown primary origin.
  • [Surgical procedure] can only be performed for patients with [disease stage] Cancer of unknown primary origin.

Prevention

  • There are no primary preventive measures available for cancer of unknown primary origin.
  • Effective measures for the primary prevention of cancer of unknown primary origin include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with Cancer of unknown primary origin are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References




 
 
 
 
 
Solitary Pulmonary Nodule Detected
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 1: Assess likelihood of cancer
Mayo Clinic Malignancy Risk Calculator
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 2: Review prior films
Is there a growth?
 
No previous films
*Refer to step 2A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes, growing
 
 
 
No, stable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 2B
Surveillance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging evaluation
 
 
 
 
 
 
 
 
 
 
 
 
 
Location
❑ Upper lobe
❑ Lower lobe
❑ Middle lobe
Size
❑ < 8mm
❑ > 8mm
Lesion characteristics
❑ Margins (irregular/regular)
❑ Shape (spiculated/rounded)
❑ Attenuation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Diagnostic Studies
❑ PET/CT scan
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low risk
❑ < 5%
 
Intermediate risk
❑ 5-65%
 
High risk
❑ > 65%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serial CT scans
 
Non-surgical biopsy
*Refer to Step 3: Treatment
 
Surgical resection
*Refer to Step 3: Treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 3: Treatment
 
 
 
 
 
 


 
 
 
 
 
Step 1: Assess likelihood of cancer
❑ Clinical judgment
Mayo Clinic Malignancy Risk Calculator
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 2: Review prior films
Is there a growth?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surveillance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging evaluation
 
 
 
 
 
 
 
 
 
 
 
 
 
Location
❑ Upper lobe
❑ Lower lobe
❑ Middle lobe
Size
❑ < 8mm
❑ > 8mm
Lesion characteristics
❑ Margins (irregular/regular)
❑ Shape (spiculated/rounded)
❑ Attenuation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Diagnostic Studies
❑ PET/CT scan
❑ Bronchoscopy
❑ Mediastinoscopy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 3
Treatment